✨ Medicine Distribution Consents




2110 NEW ZEALAND GAZETTE, No. 94 25 JUNE 2009

Dosage Form: Dispersible tablet
New Zealand Sponsor: Reckitt Benckiser (New Zealand) Limited
Manufacturer: Reckitt Benckiser Healthcare (UK) Limited, Hull, North Humberside, United Kingdom
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 5.45mg equivalent to Naloxone hydrochloride anhydrous 5mg
Oxycodone hydrochloride 10mg

Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 10.9mg equivalent to Naloxone hydrochloride anhydrous 10mg
Oxycodone hydrochloride 20mg

Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 21.8mg equivalent to Naloxone hydrochloride anhydrous 20mg
Oxycodone hydrochloride 40mg

Dosage Form: Modified release tablet
New Zealand Sponsor: Mundipharma New Zealand Limited
Manufacturers: Bard Pharmaceuticals Limited, Cambridge, United Kingdom
Mundipharma GmbH, Limburg Lahn, Germany
Product: Targin
Active Ingredients: Naloxone hydrochloride dihydrate 2.73mg equivalent to Naloxone hydrochloride anhydrous 2.5mg
Oxycodone hydrochloride 5mg

Dated this 19th day of June 2009.

JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).

go5443

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:

Schedule

Product: BYETTA 10
Active Ingredient: Exenatide 250ΞΌg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Baxter Pharmaceutical Solutions LLC, Bloomington, Indiana, United States of America
Wockhardt UK Limited, Wrexham, United Kingdom

Product: BYETTA 5
Active Ingredient: Exenatide 250ΞΌg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Baxter Pharmaceutical Solutions LLC, Bloomington, Indiana, United States of America
Wockhardt UK Limited, Wrexham, United Kingdom

Dated this 19th day of June 2009.

JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health
(pursuant to delegation given by the Minister of Health on 6 July 2001).

go5444



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2009, No 94





✨ LLM interpretation of page content

πŸ₯ Consent to Distribution of Targin Medicines

πŸ₯ Health & Social Welfare
19 June 2009
Medicines, Distribution, Targin, Naloxone, Oxycodone
  • JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health

πŸ₯ Consent to Distribution of BYETTA Medicines

πŸ₯ Health & Social Welfare
19 June 2009
Medicines, Distribution, BYETTA, Exenatide
  • JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health